Quick Read – The top pharmacy benefit managers face a structural threat from artificial intelligence, while AI-native vendors and adjacent platforms stand to benefit. – Here are five stocks ranked by how much they are affected by the disruption, from the most exposed loser to…
e most leveraged winner. – The analyst who called NVIDIA in 2010 just named his top 10 stocks and Cigna wasn’t one of them. Get them here FREE
Pharmacy benefit managers (PBMs) sit at the chokepoint of U.S. drug distribution. They negotiate rebates, design formularies, adjudicate claims, and steer patient adherence. Modern artificial intelligence (AI) is designed to compress each of these high-volume, rules-driven processes.
As autonomous prior authorization, real-time formulary optimization, and AI-driven rebate analytics scale, the Big Three PBMs face a structural threat to their legacy margin pools, while AI-native vendors and adjacent platforms stand to benefit. Below are five stocks ranked by the materiality of that disruption, from the most exposed (loser) to the most leveraged (winner). 1. Cigna: Most Exposed to PBM Disruption Cigna Group (NYSE: CI) owns Express Scripts in its Evernorth unit, now its dominant earnings engine.